睿知中国医院研究地图
候选清单

正在招募鼻咽癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由江西省肿瘤医院牵头,本站收录的另外 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 3

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
  2. 研究中心赣南医科大学第一附属医院First Affiliated Hospital of Gannan Medical University赣州医院页面
  3. 研究中心赣州市肿瘤医院Ganzhou Cancer Hospital赣州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06277050,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Pathologically confirmed nasopharyngeal carcinoma;

    入选标准第 1 条

  3. Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV ≤6 months before start of study

    排除标准第 26 条

  4. High-risk nasopharyngeal cancer meets one of three points: a. TanyN3M0; b. High-grade rENE, coalescent nodal or invasion of surrounding structures (muscle, skin, nerves, etc.); c. Detectable EBV DNA after 2 cycles of induction chemotherapy.

    入选标准第 2 条

    Has received prior therapy with an anti-PD-1 mab.

    排除标准第 4 条

  5. History of malignant tumors (except cured basal cell carcinoma or uterine cervical carcinoma in situ) within the last 5 years.

    排除标准第 2 条

    A known history of HIV infection

    排除标准第 18 条

    Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is >1000 IU/mL or patients with active hepatitis C virus (HCV) should be excluded. Note: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA <1000 IU/mL), and cured hepatitis C patients can be enrolled.

    排除标准第 19 条

    Has received any herbal medicine used to control cancer within 14 days of the start of study

    排除标准第 32 条

  6. All women with fertility potential must undergo a urine or serum pregnancy test during screening and the results are negative; 8. Written informed consent;

    入选标准第 3 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06277050,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Pathologically confirmed nasopharyngeal carcinoma;
  2. High-risk nasopharyngeal cancer meets one of three points: a. TanyN3M0; b. High-grade rENE, coalescent nodal or invasion of surrounding structures (muscle, skin, nerves, etc.); c. Detectable EBV DNA after 2 cycles of induction chemotherapy.
  3. All women with fertility potential must undergo a urine or serum pregnancy test during screening and the results are negative; 8. Written informed consent;

排除标准:Exclusion Criteria:

  1. Recurrent or distant metastatic nasopharyngeal carcinoma.
  2. History of malignant tumors (except cured basal cell carcinoma or uterine cervical carcinoma in situ) within the last 5 years.
  3. Has received any prior radiotherapy (RT) or systemic anti-cancer therapy including investigational agents for NPC
  4. Has received prior therapy with an anti-PD-1 mab.
  5. Active autoimmune diseases or history of autoimmune diseases that may relapse.
  6. Controlled Type I diabetes
  7. Hypothyroidism (provided it is managed with hormone replacement therapy only)
  8. Controlled celiac disease
  9. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia) Any other disease that is not expected to recur in the absence of external triggering factors.
  10. Any condition that required systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before the start of the study。
  11. Adrenal replacement steroid (dose ≤10 mg daily of prednisone or equivalent)
  12. Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption
  13. Short course (≤7 days) of corticosteroid prescribed prophylactically (e.g., for contrast dye allergy) or for the treatment of a non-autoimmune condition (e.g., delayed-type hypersensitivity reaction caused by contact allergen)。
  14. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.
  15. With severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc.
  16. Severe infections within 4 weeks before the start of the study, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.
  17. Received therapeutic oral or intravenous antibiotics within 2 weeks before start of the study.
  18. A known history of HIV infection
  19. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is >1000 IU/mL or patients with active hepatitis C virus (HCV) should be excluded. Note: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA <1000 IU/mL), and cured hepatitis C patients can be enrolled.
  20. Any major surgical procedure requiring general anaesthesia ≤28 days before start of study。
  21. Prior allogeneic stem cell transplantation or organ transplantation.
  22. Any of the following cardiovascular risk factors:
  23. Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤28 days before start of study
  24. Pulmonary embolism ≤28 days before start of study
  25. Any history of acute myocardial infarction ≤6 months before start of study
  26. Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV ≤6 months before start of study
  27. Any event of ventricular arrhythmia ≥Grade 2 in severity ≤6 months before start of study
  28. Any history of cerebrovascular accident ≤6 months before start of study
  29. Uncontrolled hypertension: systolic pressure ≥160 mmHg or diastolic pressure ≥100 mmHg despite anti-hypertension medications ≤28 days before start of study
  30. Any episode of syncope or seizure ≤28 days before start of study.
  31. A history of severe hypersensitivity reactions to toripalimab, capecitabine and/or any of its excipients.
  32. Has received any herbal medicine used to control cancer within 14 days of the start of study
  33. Patients with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized, except for AEs not considered a likely safety risk (e.g., alopecia, neuropathy and specific laboratory abnormalities)
  34. Concurrent participation in another therapeutic clinical study
  35. Emotional disturbance or mental illness
  36. Refusal or inability to sign informed consent

引自 ClinicalTrials.gov, NCT06277050, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06277050,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06277050